18363584. MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS simplified abstract (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY)
Contents
- 1 MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS
Organization Name
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventor(s)
Ravindra Majeti of Palo Alto CA (US)
Irving L. Weissman of Stanford CA (US)
MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS - A simplified explanation of the abstract
This abstract first appeared for US patent application 18363584 titled 'MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS
Simplified Explanation
Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
- AMLSC markers are identified and are differentially expressed compared to normal cells.
- These markers can be used for diagnostic and therapeutic purposes in acute myeloid leukemia.
Potential Applications
The identified markers of AMLSC can be used in:
- Developing targeted therapies for acute myeloid leukemia.
- Improving diagnostic methods for AML.
Problems Solved
- Early detection of AMLSC for timely treatment.
- Targeted therapy for AML patients based on specific markers.
Benefits
- Improved prognosis for AML patients.
- Personalized treatment options based on individual marker expression.
Potential Commercial Applications
- Targeted Therapies for Acute Myeloid Leukemia: Utilizing the identified markers to develop new drugs and treatment strategies for AML patients.
Possible Prior Art
There may be prior art related to identifying markers of leukemia stem cells and their differential expression compared to normal cells in the field of oncology research.
What are the specific markers identified for AMLSC in this patent application?
The specific markers identified for AMLSC in this patent application are not mentioned. Further details on the markers would be beneficial for understanding their potential applications and implications in AML research and treatment.
How do the identified markers of AMLSC compare to existing markers used in AML diagnosis and treatment?
The comparison of the identified markers of AMLSC to existing markers used in AML diagnosis and treatment is not provided in the patent application. Understanding the differences and potential advantages of the new markers over existing ones would be crucial for assessing their clinical utility and significance.
Original Abstract Submitted
Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
